Phenylketonuria Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Phenylketonuria remains an active clinical development field. One-time and precision therapies are raising the efficacy ceiling, but durability, manufacturing, small-population evidence and long-term safety remain decisive constraints. The PatSnap evidence set used here contains 64 matched trial records and 47 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| NCT07698743 | Intervention not normalized | Not Applicable; Recruiting | Sponsor not listed | France | Phenotypes related to TCA in the PCU cohort of the Reference Center for Hereditary Metabolic Diseases (from january 2026 to january 2028) | 2028-01-01 |
| NCT07694440 | MZE-782 | Phase 2; Recruiting | Maze Therapeutics, Inc. | United States | Safety and tolerability based on incidence of adverse events (AEs) (Week 0 to Week 17); For Cohorts 1A and 1B: Absolute change in plasma Phe levels from Baseline to the mean of plasma Phe levels (Baseline and Weeks 2, 3, and 4) | 2027-12-01 |
| NCT07685210 | GenSci144 | Phase 1; Recruiting | Changchun Genescience Pharmaceuticals Co., Ltd. | China | Adverse events and clinical safety indicators after a single dose. (Sign informed consent until Day3 discharge.); Change in QT/QTc interval correction ΔΔQTc after dosing. (Dynamic ECG monitoring from before to 24 hours after medication.) | 2026-09-01 |
| NCT07672756 | PJ-008 | Phase 1; Recruiting | Chongqing Paijin Biotechnology Co Ltd. | China | Adverse Events (AEs) (Day 1-29 of Phase Ia; Day 1-57 of Phase Ib) | 2027-06-01 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- A Phase 1/2 Open-label Study to Evaluate Safety, Tolerability and Efficacy of SAR444836, an Adeno-associated Viral Vector-mediated Gene Transfer of Human Phenylalanine Hydroxylase in Adult Participants with Classical Phenylketonuria (Phase 1/2): the indexed record reports Thrombocytopenia = 1 participant experienced mild-moderate thrombocytopenia around the same time-period, reported as related to SAR444836, and lasting 73 days in duration..
- BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism (Phase 3): the indexed record reports phenylalanine = -0.3 %; phenylalanine = -49.7 %.
- FDA-Approved Drugs-SEPHIENCE-CLINICAL STUDIES (Phase 3): the indexed record reports Mean Change in Blood Phe(From Baseline to Weeks 5 and 6) = -19.9 μmol/L (SE, 24.2); Mean Change in Blood Phe(From Baseline to Weeks 5 and 6) = -415.8 μmol/L (SE, 24.1).
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including MZE-782 (Phase 2; SLC6A19), GenSci144 (Phase 1; SLC6A19), PJ-008 (Phase 1; PAH). Company & Deal Intelligence records identify sponsor context for Maze Therapeutics, Inc. (MAZE), Changchun Genescience Pharmaceuticals Co., Ltd., Chongqing Paijin Biotechnology Co Ltd.. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Natural-history-aligned endpoints that remain interpretable in small heterogeneous cohorts.
- Long-term registries for durability, immunogenicity and delayed safety signals.
- Redosing, rescue and treatment-sequencing strategies after incomplete response.
- Access models that address diagnosis, manufacturing and global delivery.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Phenylketonuria has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
